In general, our findings first reveal that POLE2 overexpression inhibits ferroptosis of human gastric cancer cells through activating the NRF2/GPX4 pathway and provide a theoretical principal of molecular therapy for gastric cancer through inhibiting POLE2. This evidence concerns the gene GPX4 and gastric cancer.